Clinical Trial Update: Study of Sorafenib and Transarterial Chemoembolization (TACE) to Treat Hepatocellular Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating sorafenib combined with transarterial chemoembolization (TACE) for hepatocellular carcinoma has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma
• Hepatoma

Drugs mentioned

• Sorafenib (Sorafenib)
• Transarterial chemoembolization (TACE)

Snippet

Sponsor: Yale University | Conditions: Hepatocellular Carcinoma, Hepatoma | Phase 2 | Status: COMPLETED | Results posted: 2017-08-28